NDLI: RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS

Content Provider	PubMed Central
Author	Guido, Reifenberger Malzkorn, B. Acker, T. Bettstetter, M. Buslei, R. Deimling, A. Von Dietmaier, W. Dubbink, H. J. Eigenbrod, S. Garvalov, B. K. Gerstenmaier, U. Giese, A. Haase, D. Hasselblatt, M. Kirches, E. Koch, A. Marienfeld, R. Mittelbronn, M. Montesinos-rongen, M. Pagenstecher, A. Riemenschneider, M. J. Prinz, M. Romeike, B. Roos, A. Spiegl-kreinecker, S. Schittenhelm, J. Schlegel, J. Thal, D. R. Tops, B. B. J. Weis, J. Westphal, G. Worm, K. Felsberg, J.
Copyright Year	2014
Abstract	BACKGROUND: Molecular testing for MGMT promoter methylation has become of clinical importance in the diagnostic assessment of malignant gliomas since test results may guide therapeutic decision making, in particular in elderly patients with glioblastoma. However, the patterns and extent of MGMT promoter methylation may vary from tumor to tumor, and standardized approaches for its routine diagnostic assessment are lacking. Thus, external quality assessment (EQA) measures are required to ensure accuracy and reproducibility of results across different laboratories. METHODS: We performed an interlaboratory comparison of MGMT promoter methylation analysis involving twenty-three academic institutions in Germany, Austria and the Netherlands. Two different test rounds were carried out, the first one using high molecular weight DNA extracted from frozen tissue samples of 20 tumors and the second one using formalin-fixed paraffin-embedded tissue sections of 16 tumors. All samples were centrally retrieved from the CNS tumor tissue bank at Heinrich Heine University Düsseldorf. Each participating center evaluated the same set of samples using the locally established methods. Results were centrally collected, together with information on the individual assays and the number of tests carried out per year. RESULTS: Methylation specific-PCR was the most commonly used method at the participating centers. Other less common techniques included pyrosequencing of bisulfite-modified DNA, MethyQESD (methylation-quantification of endonuclease-resistant DNA), MLPA (Multiplex Ligation-dependent Probe Amplification), and PCR-based fragment analysis. MGMT testing results showed a good overall concordance across the participating laboratories for those tumors that either had strongly methylated or clearly unmethylated MGMT promoter sequences. However, poor concordance was obtained for cases with only weak or partial MGMT promoter methylation. CONCLUSIONS: Our study provides an overview of the current practice of MGMT testing in glioma diagnostics in a large number of different institutions. The results underscore the importance of EQA measures to assure optimal quality and interlaboratory reproducibility of test results in order to avoid wrong treatment decisions. The assessment of tumors with only partialy or weakly methylated MGMT promoter sequences is problematic and may need to be improved by testing algorithms involving more than a single technique. SECONDARY CATEGORY: Clinical Neuro-Oncology.
Related Links	http://dx.doi.org/10.1093/neuonc/nou209.30
Starting Page	49
File Format	PDF
ISSN	15228517
e-ISSN	15235866
Journal	Neuro-Oncology
Issue Number	Suppl 3
Volume Number	16
Language	English
Publisher	Oxford University Press
Publisher Date	2014-07-01
Access Restriction	Open
Rights Holder	Oxford University Press
Subject Keyword	Cancer Research Oncology Clinical Neurology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cancer Research Neurology (clinical) Oncology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation

MB-06PROGNOSTIC IMPACT OF O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION IN MEDULLOBLASTOMA

EG-02CORRELATION OF MGMT PROMOTER METHYLATION STATUS ANALYSIS USING 6 MS-MLPA PROBES AND CLINICAL RESPONSE OF TEMOZOLOMIDE IN GLIOBLASTOMA PATIENTS

Evaluation of MGMT Promoter Methylation Status and Correlation with Temozolomide Response in Orthotopic Glioblastoma Xenograft Model

Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer

TEMOZOLOMIDE FOR RECURRENT INTRACRANIAL EPENDYMOMA OF THE ADULT: PATTERNS OF RESPONSE, SURVIVAL AND CORRELATIONS WITH MGMT PROMOTER METHYLATION

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS

Similar Documents

HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation

Outcome-based determination of optimal pyrosequencing assay for MGMT methylation detection in glioblastoma patients

HDAC4, a prognostic and chromosomal instability marker, refines the predictive value of MGMT promoter methylation

MB-06PROGNOSTIC IMPACT OF O6-METHYLGUANINE-DNA METHYLTRANSFERASE (MGMT) PROMOTER METHYLATION IN MEDULLOBLASTOMA

EG-02CORRELATION OF MGMT PROMOTER METHYLATION STATUS ANALYSIS USING 6 MS-MLPA PROBES AND CLINICAL RESPONSE OF TEMOZOLOMIDE IN GLIOBLASTOMA PATIENTS

Evaluation of MGMT Promoter Methylation Status and Correlation with Temozolomide Response in Orthotopic Glioblastoma Xenograft Model

Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer

TEMOZOLOMIDE FOR RECURRENT INTRACRANIAL EPENDYMOMA OF THE ADULT: PATTERNS OF RESPONSE, SURVIVAL AND CORRELATIONS WITH MGMT PROMOTER METHYLATION

Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation

RESULTS OF THE INTERNATIONAL INTERLABORATORY COMPARISON OF MGMT PROMOTER METHYLATION ANALYSIS INVOLVING TWENTY-THREE ACADEMIC CENTERS IN GERMANY, AUSTRIA AND THE NETHERLANDS